Feasibility study of DCs/CIKs combined with thoracic radiotherapy for patients with locally advanced or metastatic non-small-cell lung cancer
/in Dendritic Cells, International Publications, NSCLCDendritic Cell-Based Immunotherapy: State of the Art and Beyond
/in Dendritic Cells, International PublicationsT-cell Landscape in a Primary Melanoma Predicts the Survival of Patients with Metastatic Disease after Their Treatment with Dendritic Cell Vaccines
/in Dendritic Cells, International Publications, Malignant MelanomaAntigen-specific T cell response from dendritic cell vaccination using side population cell-associated antigens targets hepatocellular carcinoma
/in Dendritic Cells, Hepatocellular Carcinoma, International PublicationsDendritic cell vaccines based on immunogenic cell death elicit danger signals and T cell-driven rejection of high-grade glioma
/in Dendritic Cells, Glioblastoma, Immunogenic Cell Death, International Publications, Prostate CancerImmunization of HIV-1-Infected Persons With Autologous Dendritic Cells Transfected With mRNA Encoding HIV-1 Gag and Nef: Results of a Randomized, Placebo-Controlled Clinical Trial
/in Dendritic Cells, HIV/AIDS, International PublicationsDendritic cell vaccine and cytokine-induced killer cell therapy for the treatment of advanced non-small cell lung cancer
/in Dendritic Cells, International Publications, NSCLCProphylactic vaccines are potent activators of monocyte-derived dendritic cells and drive effective anti-tumor responses in melanoma patients at the cost of toxicity
/in Dendritic Cells, International Publications, Malignant MelanomaNovel immunotherapeutic approaches to the treatment of urothelial carcinoma
/in Dendritic Cells, International Publications, Newcastle Disease Virus, Urothelial Carcinoma
IMMUN-ONKOLOGISCHES ZENTRUM KÖLN
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Hohenstaufenring 30–32
50674 Köln | Deutschland
T: +49 (0)221 – 420 399 25
E-Mail: info@iozk.de
Die IOZK Immuntherapie
Aktuelles und Int. Publikationen
- WT1-mRNA dendritic cell vaccination of patients with glioblastoma multiforme, malignant pleural mesothelioma, metastatic breast cancer, and other solid tumors: type 1 T-lymphocyte responses are associated with clinical outcome
- Autologous tumor lysate-loaded dendritic cell vaccination in glioblastoma patients: a systematic review of literature
- Retrospective Analysis of HLA Class II-Restricted Neoantigen Peptide-Pulsed Dendritic Cell Vaccine for Breast Cancer